Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Huang, He  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Zhao Y, Shi J, Luo Y, Gao F, Tan Y, Lai X, Yu J, Wei G, Huang H. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Mohty M, Duléry R, Gauthier J, Malard F, Brissot E, Aljurf M, Bazarbachi A, Chabanon C, Kharfan-Dabaja MA, Savani BN, et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020.
Wu K, Wang L-M, Liu M, Xiu Y, Hu Y, Fu S, Huang H, Xu B, Xiao H. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells. Cancer Sci. 2021.
Hwang WYk, Takahashi S, Choi B, Huang H, Kawamata S, Ng SChin, Gupta P, Hamidieh AAli, Koaykul C, Irawan C, et al. Challenges in Global Access to CAR-T cells: an Asian Perspective. Blood Cell Ther. 2024;7(1):10-13.
Yan M, Su F, Cheng F, Shi J, Zheng W, Luo Y, Wang J, Lu H, Zhou H, Huang H, et al. Chronic graft-versus-host disease-related polymyositis and myocarditis: A case report and review of the literature. Transpl Immunol. 2022:101598.
Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, Zhao P, Wang X, Li J, Zhai X, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43(4):114065.
Guan F, Yang L, Chen Y, Shi J, Song X, Lai X, Lu Y, Liu L, Ouyang G, Zhao Y, et al. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. 2024.
Yang T, Jiang B, Luo Y, Zhao Y, Ouyang G, Yu J, Lan J, Lu Y, Lai X, Ye B, et al. Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. Am J Hematol. 2023.
Zheng H, Chen Y, Luo Q, Zhang J, Huang M, Xu Y, Huo D, Shan W, Tie R, Zhang M, et al. Correction: Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges. Cell Regen. 2023;12(1):32.
Yan C-H, Liu Q-F, Wu D-P, Zhang X, Xu L-P, Zhang X-H, Wang Y, Huang H, Bai H, Huang F, et al. Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractor. Biol Blood Marrow Transplant. 2019.
Wang L, Hong R, Zhou L, Wang Y, Lv Y, Ni F, Zhang M, Zhao H, Ding S, Chang AH, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy. Cytotherapy. 2022.
Wang L, Lv Y, Zhou L, Wu S, Zhu Y, Fu S, Ding S, Hong R, Zhang M, Yu H, et al. Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies. Exp Hematol Oncol. 2024;13(1):28.
D
Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023.
Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, et al. Determining whether prophylactic antiviral treatment is necessary in HBsAg-negative/HBcAb-positive patients receiving allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Li J, Wang Q, Han Y, Jiang L, Lu S, Wang B, Qian W, Zhu M, Huang H, Qian P. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. J Hematol Oncol. 2023;16(1):65.
Zu C, Wu S, Zhang M, Wei G, Xu H, Cui J, Chang AH, Huang H, Hu Y. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Cytotherapy. 2023.
Gao F, Shi Z, Shi J, Luo Y, Yu J, Fu H, Lai X, Liu L, Yuan Z, Zheng Z, et al. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation. HLA. 2023.
Li Y, Li Y, Zhang M, Zhao H, Zhu M, Huang H, Hu Y. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation. Eur J Haematol. 2023.
Liu L, Ji X, Zhu P, Yang L, Shi J, Zhao Y, Lai X, Yu J, Fu H, Ye Y, et al. Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2023.

Pages